David Hong, Medical Oncologist at MD Anderson Cancer Center, posted on X:
“The RAS Revolution is taking off in NSCLC!
Congrats to Dr Cho presenting the new KRAsG12C inhibitor data on Elirasib and Dr Reiss presenting on Zoldonrasib! Amazing!”
Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
